5-fluorouracil

Phase 3

5-fluorouracil is one of 281 therapeutic programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

280

Competitors

Pipeline

Status by Indication[2][1]

Indication

Esophageal Squamous Cell CarcinomaRecruiting

Esophageal CancerActive, not recruiting

AdenocarcinomaRecruiting

Pancreatic Ductal AdenocarcinomaRecruiting

Colorectal CancerNot yet recruiting

Solid TumorTerminated

Neoplasm MalignantNot yet recruiting

Colorectal NeoplasmsRecruiting

Metastatic Solid TumorRecruiting

Rectal CancerActive, not recruiting

Esophageal Squamous Cell CarcinomaPreclinical

Recruiting

Esophageal CancerPhase 2

Active, not recruiting

AdenocarcinomaPhase 2

Recruiting

Pancreatic Ductal AdenocarcinomaPhase 3

Recruiting

Colorectal CancerPhase 2

Not yet recruiting

Solid TumorPhase 1

Terminated

Neoplasm MalignantPhase 3

Not yet recruiting

Colorectal NeoplasmsPhase 3

Recruiting

Metastatic Solid TumorPhase 1

Recruiting

Rectal CancerPhase 2

Active, not recruiting

Showing 10 of 18 indications

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

5-fluorouracil

Merck & Co.

Phase 3

4 2

Yervoy

Bristol-Myers Squibb

Preclinical

3 3

Nubeqa

Bayer

Preclinical

2 4

Fludara

Sanofi

Preclinical

2 5

DATROWAY

Daiichi Sankyo

Preclinical

1 6

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 7

Navmi

SSummit Therapeutics

Preclinical

1 8

Tulmimetostat

Novartis

Preclinical

1 9

Interleukin 2

EEssen Biotech

Preclinical

2 10

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Esophageal Cancer

NCT03764553

Q1 2027

Phase 2Recruiting

Liver Metastases

NCT05062317

Q2 2027

Phase 2Active, not recruiting

Pancreatic Cancer

NCT04390399

Phase 2Recruiting

Gastric Cancer

NCT06219941

Q3 2027

Phase 1Active, not recruiting

Malignant Solid Tumor

NCT06057038

PreclinicalNot yet recruiting

Leukoderma

NCT07837908

Clinical

Trials by Indication[1]

Colorectal Neoplasms4 trials

A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT06750094·700 enrolled

A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT06662786·1,000 enrolled

A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Olomorasib in Combination With Cetuximab and mFOLFOX6 in Participants With KRAS G12C-Mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer

Not yet recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT07814417·50 enrolled

Show 1 more trial

An Open-label Phase 1 Study to Investigate PF-08046050 (SGN-CEACAM5C) in Adults With Advanced Solid Tumors

Recruiting· Pfizer logo

Pfizer·Phase 1·NCT06131840·914 enrolled

Solid Tumor4 trials

ENCORAFENIB/BINIMETINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM ENCORAFENIB/BINIMETINIB CLINICAL STUDIES

Recruiting· Pfizer logo

Pfizer·Approved·NCT05203172·210 enrolled

A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors

Recruiting· Merck & Co. logo

Merck & Co.·Phase 1·NCT05067283·830 enrolled

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06576037·128 enrolled

Show 1 more trial

A Phase 1/2 Study of ASP1570 as Monotherapy and in Combination With Pembrolizumab and/or Standard Therapies Including Chemotherapy and/or Immunotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Terminated· Astellas logo

Astellas·Phase 1·NCT05083481·226 enrolled

Colorectal Cancer3 trials

A Phase I, Multicenter, Open-Label First in Human Study of Anti-CEACAM5 Antibody Drug Conjugate M9140 in Participants With Advanced Solid Tumors (PROCEADE-CRC-01)

Active, not recruiting· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 1·NCT05464030·220 enrolled

A Randomized, Open Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo® in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care for First-line Treatment of Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

Recruiting· Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd·Phase 2·NCT06948448·144 enrolled

A Phase 2 Clinical Trial of Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer

Not yet recruiting·WWashington University School of Medicine·Phase 2·NCT07662031·25 enrolled

Gastroesophageal Adenocarcinoma2 trials

A Master Protocol of an Open-Label, Multi-Drug, Multi-Center, Phase II Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (GEMINI-PeriOp GC)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT07069712·100 enrolled

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma): Substudy 06C

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06469944·160 enrolled

Pancreatic Cancer2 trials

Open-label, Randomized, Comparative Phase 2 Study of Combination Immunotherapy Plus Standard-of-care Chemotherapy Versus Standard-of-care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Active, not recruiting·IImmunityBio, Inc.·Phase 2·NCT04390399·328 enrolled

RASolute 305: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (Modified FOLFIRINOX or Gemcitabine Plus Nab-Paclitaxel) With or Without Zoldonrasib (RMC-9805) as First-line Treatment in Patients With Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma

Recruiting· Revolution Medicines logo

Revolution Medicines·Phase 3·NCT07621718·670 enrolled

37 more indications

Esophageal Squamous Cell Carcinoma2 trials

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06780111·298 enrolled

A Phase II/III Randomized Controlled Clinical Study of BL-B01D1 for Injection in Combination With Tislelizumab With or Without 5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)

Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Preclinical·NCT07554456·90 enrolled

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer2 trials

A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination With Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors Are HER2-negative, Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-Positive

Recruiting· Astellas logo

Astellas·Phase 3·NCT06901531·500 enrolled

A Phase 4, Multicenter, Open-label, Safety and Antitumor Activity Study of Zolbetuximab Plus mFOLFOX6 or CAPOX as Firstline Treatment in Indian Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Not yet recruiting· Astellas logo

Astellas·Approved·NCT07829757·50 enrolled

Pancreatic Ductal Adenocarcinoma2 trials

A Phase 1a/1b Trial of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 1·NCT06586515·630 enrolled

An Open Labelled Phase III Adjuvant Trial of Disease-free Survival in Patients With Resected Pancreatic Ductal Adenocarcinoma Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature

Recruiting·JJohn Neoptolemos·Phase 3·NCT05314998·394 enrolled

Gastric Cancer2 trials

A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in First-Line Claudin18.2-Positive, HER2-Negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07431281·2,130 enrolled

A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT06219941·226 enrolled

Esophageal Cancer2 trials

A Single-Arm, Multicenter Phase 2 Study of Neoadjuvant Pembrolizumab With Trastuzumab and Chemotherapy in Resectable HER2+ Esophagogastric Tumors

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06123338·49 enrolled

Liposomal iRInotecan, Carboplatin or oXaliplatin in the First Line Treatment of Esophagogastric Cancer: a Randomized Phase 2 Study

Active, not recruiting·AAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)·Phase 2·NCT03764553·320 enrolled

Gastroesophageal Junction Adenocarcinoma2 trials

A Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Terminated· Roche logo

Roche·Preclinical·NCT03281369·219 enrolled

RACE-trial: Neoadjuvant Radiochemotherapy Versus Chemotherapy for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) A Randomized Phase III Joint Study of the AIO, ARO and DGAV

Completed·UUniversitätsmedizin Mannheim·Phase 3·NCT04375605·342 enrolled

Colon Adenocarcinoma1 trial

A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 Versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06997497·477 enrolled

Biliary Tract Cancer1 trial

A Prospective, Open-label, Randomized Controlled Clinical Study of Hepatic Arterial Infusion Chemotherapy (HAIC) Versus Capecitabine as Adjuvant Therapy for Biliary Tract Malignancies After Radical Resection

Not yet recruiting·ZZhai Wenlong·Phase 3·NCT07916844·90 enrolled

Malignant Solid Tumor1 trial

A Phase 1 Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of GEN1042 Monotherapy and in Combination With Pembrolizumab ± Chemotherapy in Japanese Subjects With Malignant Solid Tumors

Active, not recruiting· Genmab logo

Genmab·Phase 1·NCT06057038·8 enrolled

Peritoneal Mesothelioma1 trial

Individualized Response Assessment to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Primaries

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04847063·60 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

A Phase 1b/2 Study of ASP388B as Monotherapy and in Combination With Standard Therapies in Participants With Locally Advanced Unresectable or Metastatic Solid Tumors

Recruiting· Astellas logo

Astellas·Preclinical·NCT07730021·392 enrolled

Advanced Esophageal Squamous Cell Carcinoma1 trial

A Phase 2 Study of Tislelizumab Administered With Alternative Dosing Schedules Plus Chemotherapy as First-line Treatment in Japanese Patients With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Recruiting·BBeOne Medicines·Phase 2·NCT07733180·30 enrolled

Solid Neoplasms1 trial

An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors

Completed· Takeda logo

Takeda·Preclinical·NCT04420884·248 enrolled

Gastric Neoplasms1 trial

A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)

Active, not recruiting· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 3·NCT05152147·920 enrolled

HER2-positive Gastric Cancer1 trial

A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06764875·840 enrolled

Metastatic Colorectal Cancer (CRC)1 trial

A Prospective, Multicenter, Randomized Controlled, Phase II Study to Evaluate the Efficacy and Safety of FOLFOX8 Versus mFOLFOX6 Combined With Bevacizumab or Cetuximab as First-Line Treatment for Unresectable Metastatic Colorectal Cancer

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT07621497·229 enrolled

Advanced Unresectable Gastric Adenocarcinoma1 trial

An Open-Label, Single-Arm, Phase 2 Study to Evaluate the Efficacy and Safety of Tislelizumab Plus Chemotherapy in a First-Line Setting for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in US Racial and Ethnic Minority Patients

Recruiting·BBeOne Medicines·Phase 2·NCT07554521·30 enrolled

Metastatic Gastric Adenocarcinoma1 trial

A Phase 3, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting·BBeOne Medicines·Phase 3·NCT07043400·351 enrolled

Malignant Neoplam1 trial

A Phase 2, Open-label Clinical Study to Evaluate the Safety and Efficacy of MK-2010 as Monotherapy and in Combination

Not yet recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT07793942·480 enrolled

Carcinoma of the Anal Canal1 trial

A Pilot Feasibility Study of Definitive Concurrent Chemoradiation With Pencil Beam Scanning Proton Beam in Combination With 5-Fluorouracil and Mitomycin-C for Carcinoma of the Anal Canal

Completed·MMassachusetts General Hospital·Phase 1·NCT01858025·25 enrolled

Head and Neck Cancer1 trial

A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Completed· Incyte logo

Incyte·Phase 3·NCT03358472·89 enrolled

Uterine Cervical Neoplasms1 trial

A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Co-formation of Vibostolimab (MK-7684) With Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT05007106·611 enrolled

Stage II Rectal Cancer AJCC v81 trial

The Janus Rectal Cancer Trial: A Randomized Phase II/III Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy Regarding Clinical Complete Response and Disease-free Survival in Patients With Locally Advanced Rectal Cancer

Active, not recruiting·AAlliance for Clinical Trials in Oncology·Preclinical·NCT05610163·760 enrolled

Advanced Solid Tumours1 trial

A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT05647122·190 enrolled

Leukoderma1 trial

Fractional Co2 Laser vs Dermabrasion 5-Flurouracil Delivery in Acquired Leukoderma: A Comparative Study

Not yet recruiting·AAl-Azhar University·Preclinical·NCT07837908·16 enrolled

Endometrial Cancer1 trial

A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT05489211·454 enrolled

Metastatic Pancreatic Ductal Adenocarcinoma1 trial

A Phase 2 Study Assessing Utility of ctDNA in Early Switch of First-line Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting·UUniversity of Miami·Phase 2·NCT07096362·50 enrolled

Metastatic Pancreatic Cancer1 trial

A Randomized, Controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of YL201 Versus Liposomal Irinotecan in Combination With 5-Fluorouracil/Leucovorin in Participants With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed Prior Gemcitabine-based Systemic Therapy

Not yet recruiting·MMediLink Therapeutics (Suzhou) Co., Ltd.·Phase 3·NCT07803783·320 enrolled

Neoplasm Malignant1 trial

A Prospective, Open-label, Phase 4 Study to Evaluate the Safety of Pembrolizumab (KEYTRUDA®) in Combination With Indication-specific Chemotherapy or Chemoradiotherapy in Participants Across Multiple Indications in India (KEYNOTE-G44)

Not yet recruiting· Merck & Co. logo

Merck & Co.·Approved·NCT07801027·150 enrolled

Gastric Carcinoma1 trial

A Single-Arm, Phase II Study of Ivonescimab in Combination With FOLFOX in Advanced HER2 Negative Gastroesophageal Adenocarcinomas

Recruiting·MMassachusetts General Hospital·Phase 2·NCT07070466·40 enrolled

Rectal Cancer1 trial

A Phase II Multicenter Randomized Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT02008656·358 enrolled

Advanced Colorectal Cancer1 trial

Phase Ib/II Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of MRG007 Combination Therapy in Patients With Advanced Colorectal Cancer

Not yet recruiting·LLepu Biopharma Co., Ltd.·Preclinical·NCT07737600·316 enrolled

Adenocarcinoma1 trial

Phase II Study of NALIRIFOX (Nanoliposomal Irinotecan + Oxaliplatin With Fluorouracil and Folinic Acid) in Advanced Unresectable Small Bowel Tumors

Recruiting·TTiago Biachi de Castria·Phase 2·NCT06835387·36 enrolled

Locally-advanced Rectal Cancer1 trial

Phase II Study of Short-course Radiotherapy Followed by Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: the ShorTrip Study

Active, not recruiting·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT05253846·63 enrolled

Liver Metastases From Colorectal Cancer (mCRC)1 trial

Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Two or Three-line Therapy

Enrolling by invitation·FFudan University·Phase 2·NCT07441369·16 enrolled

Metastatic Solid Tumor1 trial

A Phase 1B, Multicenter, Open-Label Study of the Safety and Efficacy of CHS-114 in Combination With Toripalimab With or Without Other Treatments in Participants With Advanced or Metastatic Solid Tumors (TREGCHECK 102)

Recruiting·CCoherus Oncology, Inc.·Phase 1·NCT06657144·154 enrolled

Liver Metastases1 trial

Risk-Stratified Adjuvant Therapy: ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05062317·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 58 trial records for 5-fluorouracil. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 5-fluorouracil. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Merck & Co.

5-fluorouracil

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Q3 2027

Trials by Indication[1]

Colorectal Neoplasms4 trials

Solid Tumor4 trials

Colorectal Cancer3 trials

Gastroesophageal Adenocarcinoma2 trials

Pancreatic Cancer2 trials

Esophageal Squamous Cell Carcinoma2 trials

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer2 trials

Pancreatic Ductal Adenocarcinoma2 trials

Gastric Cancer2 trials

Esophageal Cancer2 trials

Gastroesophageal Junction Adenocarcinoma2 trials

Colon Adenocarcinoma1 trial

Biliary Tract Cancer1 trial

Malignant Solid Tumor1 trial

Peritoneal Mesothelioma1 trial

Locally Advanced or Metastatic Solid Tumors1 trial

Advanced Esophageal Squamous Cell Carcinoma1 trial

Solid Neoplasms1 trial

Gastric Neoplasms1 trial

HER2-positive Gastric Cancer1 trial

Metastatic Colorectal Cancer (CRC)1 trial

Advanced Unresectable Gastric Adenocarcinoma1 trial

Metastatic Gastric Adenocarcinoma1 trial

Malignant Neoplam1 trial

Carcinoma of the Anal Canal1 trial

Head and Neck Cancer1 trial

Uterine Cervical Neoplasms1 trial

Stage II Rectal Cancer AJCC v81 trial

Advanced Solid Tumours1 trial

Leukoderma1 trial

Endometrial Cancer1 trial

Metastatic Pancreatic Ductal Adenocarcinoma1 trial

Metastatic Pancreatic Cancer1 trial

Neoplasm Malignant1 trial

Gastric Carcinoma1 trial

Rectal Cancer1 trial

Advanced Colorectal Cancer1 trial

Adenocarcinoma1 trial

Locally-advanced Rectal Cancer1 trial

Liver Metastases From Colorectal Cancer (mCRC)1 trial

Metastatic Solid Tumor1 trial

Liver Metastases1 trial

References

Drug Info

Quick Facts

Related News